Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price target from $41 to $48.
Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price target from $41 to $48.